Skip to main content

Mark F. Warner, MD

08/01/2008
Enoxaparin, a low molecular weight heparin, has demonstrated superior efficacy over unfractionated heparin (UFH) in the medical management of acute coronary syndromes (ACS), e.g., unstable angina and non-ST elevation myocardial infarction.1...
Enoxaparin, a low molecular weight heparin, has demonstrated superior efficacy over unfractionated heparin (UFH) in the medical management of acute coronary syndromes (ACS), e.g., unstable angina and non-ST elevation myocardial infarction.1...
Enoxaparin, a low molecular...
08/01/2008
Journal of Invasive Cardiology
Original Contribution
08/01/2008
ABSTRACT: The use of intravenous enoxaparin, a glycoprotein (GP) IIb/IIIa inhibitor, during percutaneous coronary intervention (PCI) has been shown to be safe and to possibly reduce in-hospital and 30-day major adverse cardiac events (MACE)....
ABSTRACT: The use of intravenous enoxaparin, a glycoprotein (GP) IIb/IIIa inhibitor, during percutaneous coronary intervention (PCI) has been shown to be safe and to possibly reduce in-hospital and 30-day major adverse cardiac events (MACE)....
ABSTRACT: The use of intravenous...
08/01/2008
Journal of Invasive Cardiology